Translarna Approval Status
- FDA approved: No
- Brand name: Translarna
- Generic name: ataluren
- Company: PTC Therapeutics, Inc.
- Treatment for: Duchenne Muscular Dystrophy
Translarna (ataluren) is a protein restoration therapy in development for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD).
Development Status and FDA Approval Process for Translarna
|Oct 25, 2017||PTC Therapeutics Receives Complete Response Letter for Ataluren's NDA|
|Mar 6, 2017||PTC Therapeutics Announces FDA Acknowledgment of New Drug Application Filing for Translarna for the Treatment of Nonsense Mutation Duchenne Muscular Dystrophy|
|Oct 17, 2016||PTC Therapeutics Provides Regulatory Update on Translarna (ataluren) for Nonsense Mutation Duchenne Muscular Dystrophy|
|Feb 23, 2016||PTC Receives Refuse to File Letter from FDA for Translarna (ataluren)|
|Oct 15, 2015||PTC Announces Results from Phase 3 ACT DMD Clinical Trial of Translarna (ataluren) in Patients with Duchenne Muscular Dystrophy|
|Dec 23, 2014||PTC Therapeutics Begins Rolling NDA Submission to the FDA for Translarna to Treat Duchenne Muscular Dystrophy|
|Jun 8, 2012||Top-line Data From Phase 3 Trial of Ataluren in Patients with Nonsense Mutation Cystic Fibrosis Show Promising Results|
|Jul 1, 2011||Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal|
|Oct 19, 2010||Pivotal Data Presented at the World Muscle Society Congress Suggest Ataluren Slows the Loss of Walking Ability in Patients with Nonsense Mutation Duchenne/Becker Muscular Dystrophy|
|Mar 3, 2010||PTC Therapeutics and Genzyme Corporation Announce Preliminary Results from the Phase 2b Clinical Trial of Ataluren for Nonsense Mutation Duchenne/Becker Muscular Dystrophy|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.